Advertisement

Advertisement

SOLTF Stock Latest News

Nxera Pharma Gains $8.6 Million Milestone as Lilly-Backed Sleep Disorder Pipeline Advances

Company AnnouncementsNxera Pharma Gains $8.6 Million Milestone as Lilly-Backed Sleep Disorder Pipeline Advances

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

PremiumCompany Announcements

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

1M ago

Sosei Group Earnings Call Signals Profitable Growth

PremiumCompany Announcements

Sosei Group Earnings Call Signals Profitable Growth

2M ago

Nxera Pharma Builds APAC Footprint and Books Milestone Windfall in Q2 2026

PremiumCompany Announcements

Nxera Pharma Builds APAC Footprint and Books Milestone Windfall in Q2 2026

2M ago

Nxera Pharma Swings to Profit on Revenue Jump, Keeps 2026 Outlook Intact

PremiumCompany Announcements

Nxera Pharma Swings to Profit on Revenue Jump, Keeps 2026 Outlook Intact

2M ago

Nxera Pharma Secures Fourth AbbVie Milestone in Neurology Collaboration

PremiumCompany AnnouncementsNxera Pharma Secures Fourth AbbVie Milestone in Neurology Collaboration

3M ago

Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery

Company Announcements

Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery

4M ago

Nxera Wins Fast-Track and Orphan Status in Korea for Duchenne Drug Vamorolone

Company Announcements

Nxera Wins Fast-Track and Orphan Status in Korea for Duchenne Drug Vamorolone

4M ago

Nxera trims RSU share issuance after partial forfeiture

PremiumCompany Announcements

Nxera trims RSU share issuance after partial forfeiture

5M ago

Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal

PremiumCompany Announcements

Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal

5M ago

Nxera Pharma Returns to Profit on Surging Q1 Revenue, Keeps 2026 Guidance Unchanged

PremiumCompany Announcements

Nxera Pharma Returns to Profit on Surging Q1 Revenue, Keeps 2026 Guidance Unchanged

5M ago

Nxera Pharma Posts Strong Q1 2026 Momentum on Asia-Pacific Deals and Milestones

PremiumCompany Announcements

Nxera Pharma Posts Strong Q1 2026 Momentum on Asia-Pacific Deals and Milestones

5M ago

Nxera Pharma Secures Third AbbVie Milestone in Neurology Collaboration

PremiumCompany AnnouncementsNxera Pharma Secures Third AbbVie Milestone in Neurology Collaboration

6M ago

Nxera Pharma Issues New Shares to Fund Japan Employee Stock Plan and Expand RSU Program

Company Announcements

Nxera Pharma Issues New Shares to Fund Japan Employee Stock Plan and Expand RSU Program

6M ago

Nxera Wins Taiwan Approval for QUVIVIQ Insomnia Drug, Eyes 2026 Launch

Company Announcements

Nxera Wins Taiwan Approval for QUVIVIQ Insomnia Drug, Eyes 2026 Launch

6M ago

Nxera Wins US$22.5m Milestone as Neurocrine Starts Phase 2 Schizophrenia Trial

PremiumCompany Announcements

Nxera Wins US$22.5m Milestone as Neurocrine Starts Phase 2 Schizophrenia Trial

6M ago

Nxera Pharma Hits Second Milestone in Lilly Metabolic Disease Partnership

PremiumCompany Announcements

Nxera Pharma Hits Second Milestone in Lilly Metabolic Disease Partnership

6M ago

Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength

PremiumCompany Announcements

Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength

6M ago

Nxera Pharma Refreshes Board While Maintaining Core Leadership Team

PremiumCompany Announcements

Nxera Pharma Refreshes Board While Maintaining Core Leadership Team

7M ago

Nxera Pharma Secures $3 Million Milestone Payment from Centessa

PremiumCompany AnnouncementsNxera Pharma Secures $3 Million Milestone Payment from Centessa

7M ago

Nxera Pharma Files for South Korean Approval of Insomnia Drug Daridorexant

Company Announcements

Nxera Pharma Files for South Korean Approval of Insomnia Drug Daridorexant

7M ago

Sosei Group Earnings Call Marks Cautious Transition

Company Announcements

Sosei Group Earnings Call Marks Cautious Transition

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >